Cargando…

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer

OBJECTIVE: The outcome of the androgen-deprivation therapy (ADT) may be affected by metabolic diseases such as diabetes mellitus (DM) and dyslipidemia and/or by their treatments. We aimed to evaluate the prognostic impact of these disorders and corresponding medications in Japanese men treated with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirata, Yu, Shiota, Masaki, Kobayashi, Takeshi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, Eto, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Pacific Prostate Society 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962726/ https://www.ncbi.nlm.nih.gov/pubmed/31970142 http://dx.doi.org/10.1016/j.prnil.2019.10.003

Ejemplares similares

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
por: Shiota, Masaki, et al.
Publicado: (2018)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2
por: Itsumi, Momoe, et al.
Publicado: (2016)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
por: Shiota, Masaki, et al.
Publicado: (2015)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide
por: Kashiwagi, Eiji, et al.
Publicado: (2022)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
por: Ushijima, Miho, et al.
Publicado: (2022)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
por: Blas, Leandro, et al.
Publicado: (2021)

The Role of Nuclear Receptors in Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2019)

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
por: Blas, Leandro, et al.
Publicado: (2023)

Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
por: Johnson, Matthew E., et al.
Publicado: (2012)

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade
por: Tanaka, Kentaro, et al.
Publicado: (2018)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
por: Takeuchi, Ario, et al.
Publicado: (2020)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?
por: Essien, Okon Ekwere, et al.
Publicado: (2016)

Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review
por: Bressi, Barbara, et al.
Publicado: (2020)

Risk of colorectal adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer; a nationwide cohort study
por: Shore, Richard, et al.
Publicado: (2023)

Antiandrogenic Effects of a Polyphenol in Carex kobomugi through Inhibition of Androgen Synthetic Pathway and Downregulation of Androgen Receptor in Prostate Cancer Cell Lines
por: Kudo, Yudai, et al.
Publicado: (2022)

Feasibility and safety of physical exercise in men with prostate cancer receiving androgen deprivation therapy and radiotherapy: a study protocol
por: Bressi, Barbara, et al.
Publicado: (2022)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
por: Shiota, Masaki, et al.
Publicado: (2016)

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
por: Shiota, Masaki, et al.
Publicado: (2022)

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
por: Blas, Leandro, et al.
Publicado: (2022)

Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy
por: Ouyang, Wei, et al.
Publicado: (2021)

Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
por: Kato, Koji, et al.
Publicado: (2020)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy
por: Blow, Tahj A., et al.
Publicado: (2023)

How do we define “castration” in men on androgen deprivation therapy?
por: Itty, Sarin, et al.
Publicado: (2020)

Androgen deprivation and SARS-CoV-2 in men with prostate cancer
por: Koskinen, M., et al.
Publicado: (2020)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6cg6i33kfuednb6mlafrcctosk